Get the Daily Brief
Latest Biotech News
Merck splits oncology — reorg ahead of Keytruda cliff
Merck announced an internal reorganization that separates its oncology business into a standalone unit as the company prepares for the anticipated loss of Keytruda exclusivity in 2028. The...
Novo’s CagriSema falls short — Zepbound wins head‑to‑head
Novo Nordisk reported that its investigational combination obesity therapy, CagriSema, failed to show noninferiority to Eli Lilly’s marketed Zepbound in a head‑to‑head Phase 3 study (REDEFINE 4)....
Sequencing arms race... Illumina and Ultima upgrade platforms
Two major players in high‑throughput sequencing disclosed platform upgrades aimed at increasing throughput and accuracy and compressing run times. Ultima Genomics launched its UG200 series and...
Switchable CAR‑T: drug control may curb toxicity
Researchers at EPFL reported a preclinical CAR‑T system, DROP‑CAR, that can be rapidly and reversibly switched off using the clinically approved cancer drug venetoclax. The team published their...
Generate plans $425M IPO — bankrolls antibody phase‑3 asthma trials
Generate:Biomedicines filed to raise up to $425 million in an IPO to fund its lead antibody through Phase 3 respiratory disease trials. The Flagship‑backed, AI‑driven startup said proceeds would...
Syndex raises $15.5M to scale methylation‑preserving PCR
Syndex Bio closed a $15.5 million seed round led by Arch Venture Partners to commercialize mcPCR, a methylation‑preserving PCR technology. The company said the platform copies methylation marks...
Korsana raises $175M — advances brain‑penetrant Alzheimer’s program
Korsana Biosciences announced a $175 million financing to advance a preclinical Alzheimer’s program built around a platform that delivers antibodies across the blood‑brain barrier. The company...
Gossamer’s PAH drug fails Phase 3 — shares collapse
Gossamer Bio reported that its Phase 3 PROSERA study of inhaled tyrosine kinase inhibitor seralutinib in pulmonary arterial hypertension missed the primary endpoint, with an observed...
Gilead pays $7.8B — Arcellx deal brings anito‑cel in‑house
Gilead Sciences agreed to acquire Arcellx for $7.8 billion to take full control of anito‑cel, a BCMA‑directed CAR‑T candidate nearing regulatory review. The purchase price includes $115 per share...
FDA unveils pathway for individualized therapies: plausible‑mechanism guidance
The U.S. Food and Drug Administration released draft guidance formalizing the "plausible mechanism" framework to accelerate approvals for individualized cell and gene therapies targeting extremely...
Novo’s CagriSema falls short — Zepbound wins head‑to‑head
Novo Nordisk’s next‑generation obesity candidate CagriSema failed to meet non‑inferiority against Eli Lilly’s Zepbound in a head‑to‑head late‑stage trial, delivering roughly 20% average weight...
Merck splits businesses — standalone oncology arm created ahead of Keytruda cliff
Merck reorganized its human health operations into two separate businesses, creating a standalone oncology unit and a second division for specialty, pharma and infectious diseases. The change...
Sequencer showdown: Illumina upgrades NovaSeq X — Ultima launches UG200
Two major moves in high‑throughput sequencing sharpen competition: Illumina pledged incremental NovaSeq X upgrades to raise output and accuracy—aiming for Q50 kits and expanded flow‑cell...
Drug‑switchable CAR T: DROP‑CAR offers reversible control with venetoclax
Researchers at EPFL reported a preclinical CAR‑T platform, named DROP‑CAR, that can be rapidly and reversibly deactivated using the approved cancer drug venetoclax. Published in Nature Chemical...
Explainable AI spots hidden pancreatic traits linked to type‑2 diabetes
A team from the German Center for Diabetes Research trained explainable deep‑learning models on gigapixel microscopy of pancreatic tissue from living donors and identified microscopic features...
Syndex raises $15.5M — mcPCR to preserve methylation during amplification
Syndex Bio closed a $15.5 million seed round led by Arch Venture Partners to develop mcPCR, a methylation‑preserving PCR amplification technology. mcPCR uses engineered methyltransferases to copy...
Generate files for IPO — $425M to fund antibody phase‑3 trials
Generate:Biomedicines is planning an initial public offering to raise up to $425 million to advance its lead antibody into phase‑3 respiratory disease trials and to bankroll other clinical...
Gossamer’s seralutinib fails phase‑III — Prosera miss triggers sharp sell‑off
Gossamer Bio reported that its Phase‑III Prosera study of inhaled tyrosine kinase inhibitor seralutinib in pulmonary arterial hypertension missed the primary endpoint for six‑minute walk distance....
Gilead to buy Arcellx for $7.8B – bets company on BCMA CAR‑T anito‑cel
Gilead agreed to acquire Arcellx for $7.8 billion to secure full control of anitocabtagene autoleucel (anito‑cel), a BCMA‑directed CAR‑T therapy nearing regulatory review. The deal combines...
Novo’s CagriSema falls short in head‑to‑head vs Lilly’s Zepbound
Novo Nordisk reported that its investigational combination obesity shot CagriSema failed to show non‑inferiority to Eli Lilly’s marketed Zepbound in a head‑to‑head Phase 3 trial. CagriSema...